ADC Process Development &
Conjugation CMC Consulting

Build an ADC manufacturing path shaped around conjugation,
purification, containment, and late-stage control strategy.

Modalities Supported

ADC Process Development Conjugation Strategy Built for Scale, Control, and CMC Review

ADC manufacturing performance depends on the combined behavior of the antibody, linker-payload, conjugation chemistry, purification train, and containment model. DES Pharma supports sponsors developing cleavable and non-cleavable ADC platforms (including auristatin, maytansinoid, and topoisomerase I payload systems) through process design that works at scale and supports CMC review. We help teams turn early conjugation concepts into repeatable manufacturing processes with defined control points for DAR, drug load distribution, residual free payload, unconjugated antibody, aggregation, and yield.

Whether the program uses lysine conjugation, reduced interchain cysteine conjugation, or a site-specific platform, we focus on process decisions that support batch consistency and make later analytical and validation work easier to manage. Our support covers reaction development, quench strategy, purification design, formulation interfaces, tech transfer packages, and late-stage process characterization. The goal is to build an ADC process that is phase-appropriate, scalable, and ready to support clinical supply, PPQ planning, and commercial control strategy.

 

ADC Conjugation & Manufacturing Focus Areas

Where ADC programs most often lose time, and how we address them

We focus on the parts of ADC process development where programs most often lose time: conjugation reproducibility, DAR distribution, free payload clearance, aggregate control, hold-step stability, and transfer into contained GMP operations.

Linker-Payload Compatibility
Lysine / Cysteine / Site-Specific Conjugation
DAR Target & Drug Load Distribution
Reaction Condition Screening
Purification Train Design
Aggregate & Fragment Risk Reduction
Formulation & Hold-Step Planning
Scale-Up & Tech Transfer Packages
PPQ Readiness & Control Strategy

Phase-Appropriate CMC Approach Cutting Out Excess & Risks
Across Every Development Stage

Phase-appropriate process development that ensures batch consistency, data-driven improvements, and efficient progress from pre-clinical through commercial ADC launch.

🧾
Pre-Clinical

Begin with the end state in mind: build ADC conjugation foundations that scale

🧾
Phase 1 / 2

Lay the groundwork for robust clinical supply and commercial product launch

🧾
Pre-Commercial Launch

Ensure process control, consistent product quality, and submission readiness

🧾
Post-Commercial Support

Maintain compliance, support lifecycle management, and expand market reach

Integrated CMC Strategy Integrated ADC Process Strategy

ADC process work is more effective when conjugation strategy, analytical planning, and GMP operating requirements are built as one connected program. DES Pharma helps teams line these pieces up early so later development, transfer, and filing work move more smoothly. We focus on the factors that most often determine whether an ADC process scales well: DAR distribution, residual free payload clearance, unconjugated antibody control, aggregate management, hold-step stability, and containment fit.

Clinical Supply Chain Consulting

Conjugation Strategy Selection

Evaluation of lysine, cysteine, and site-specific platforms against reproducibility, heterogeneity, and transferability criteria, matched to the antibody format, intended DAR, and downstream analytical strategy.

DAR Control & Distribution

Setting DAR targets informed by product performance and manufacturing consistency. Building control approaches that connect reaction conditions to drug load outcomes and remain defensible through IND amendment and BLA filing.

Purification Design

Designing purification trains for payload clearance, unconjugated antibody removal, aggregate reduction, and yield balance, including resin selection, step sequencing, and in-process hold compatibility.

Scale-Up Planning

Addressing mixing regime, hold-time assumptions, sampling access, and equipment constraints across bench, clinical, and commercial scales. Developing scale-down models and transfer criteria for CDMO operations.

Containment Readiness

Assessing OEB requirements for the payload class, identifying contained conjugation suite options, developing potent compound handling SOPs, and planning cleaning validation approaches for ADC manufacturing equipment.

Why DES Pharma for ADC Process Development Rational Design, Reliable Results
Emphasizing Process Design & Product Quality

Our approach integrates conjugation science, manufacturing realism, and regulatory CMC thinking from the first process discussion.

Phase-Appropriate Design

Process plans that support the current development stage without sacrificing the structural decisions needed for the eventual commercial process.

Integrated Process & Analytics

Analytical planning built alongside process decisions so QC method development, specification setting, and stability work are easier to execute at each phase transition.

Manufacturing Realism

Recommendations grounded in plant execution realities (equipment fit, batch scale, hold logistics, and GMP documentation), not bench chemistry assumptions alone.

Containment-Aware Planning

Potent compound handling, OEB classification, suite selection, and cleaning validation integrated into process design from the start, not retrofitted at tech transfer.

Transfer-Ready Documentation

Tech transfer packages, CDMO communication materials, engineering lot reports, and PPQ preparation documents built to be usable by operations teams, not just internal scientists.

Commercial Pathway Planning

Scale, comparability, control strategy, and filing readiness are addressed as a coherent program, so late-stage transitions and post-approval changes are planned, not reactive.

Our Approach Supply Planning & Commercial Readiness
Recommended Process Planning Framework

A structured approach to ADC process development that connects early conjugation decisions to later-stage manufacturing control, regulatory filing, and commercial lifecycle management.

Clinical Supply Chain Consulting

Define Product Intent

Establish the target DAR range, conjugation approach, payload class, and key quality attribute risks that will govern process design decisions.

Map the Reaction Strategy

Define stoichiometry, reduction state, quench logic, solvent exposure parameters, and in-process sampling points to establish a reproducible conjugation sequence.

Design the Purification Train

Sequence purification steps for free payload removal, unconjugated antibody control, aggregate management, and yield balance, with step-specific performance targets.

Link to Analytics

Select in-process and release methods capable of monitoring process outputs and supporting future specifications aligned with ICH Q6B and analytical lifecycle expectations under ICH Q14 / Q2(R2).

Assess GMP Execution

Evaluate containment needs, equipment fit, material flow, cleaning strategy, and batch record implications before transfer to a GMP manufacturing environment.

Plan for Scale & Lifecycle

Frame tech transfer expectations, process characterization study scope, PPQ planning, and post-approval change management strategy as a connected CMC lifecycle program.

Get Started Build Your ADC Process Strategy for Scale, Control, and Filing Readiness

Connect with our ADC process development team to discuss your conjugation platform, DAR control approach, or commercial manufacturing pathway.